Share on StockTwits

Incyte (NASDAQ:INCY) EVP Richard S. Levy sold 8,000 shares of the company’s stock on the open market in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $51.97, for a total value of $415,760.00. Following the completion of the sale, the executive vice president now directly owns 4,301 shares in the company, valued at approximately $223,523. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Shares of Incyte (NASDAQ:INCY) traded up 0.85% on Tuesday, hitting $52.12. 554,221 shares of the company’s stock traded hands. Incyte has a 52-week low of $26.51 and a 52-week high of $70.86. The stock has a 50-day moving average of $49.81 and a 200-day moving average of $54.19. The company’s market cap is $8.778 billion.

Incyte (NASDAQ:INCY) last issued its quarterly earnings data on Thursday, July 31st. The company reported ($0.22) earnings per share for the quarter, missing the analysts’ consensus estimate of $0.05 by $0.27. The company had revenue of $99.58 million for the quarter, compared to the consensus estimate of $140.72 million. During the same quarter last year, the company posted $0.05 earnings per share. Incyte’s revenue was down 2.1% compared to the same quarter last year. On average, analysts predict that Incyte will post $-0.36 earnings per share for the current fiscal year.

A number of research firms have recently commented on INCY. Analysts at Zacks reiterated a “neutral” rating on shares of Incyte in a research note on Tuesday, August 5th. They now have a $51.00 price target on the stock. Separately, analysts at Nomura reiterated a “buy” rating on shares of Incyte in a research note on Thursday, July 24th. They now have a $90.00 price target on the stock. Finally, analysts at Nomura reiterated a “buy” rating on shares of Incyte in a research note on Monday, June 2nd. They now have a $90.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and twelve have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $62.33.

Incyte Corporation (NASDAQ:INCY) is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat serious unmet medical needs.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.